ATE262336T1 - Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen - Google Patents

Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen

Info

Publication number
ATE262336T1
ATE262336T1 AT98957487T AT98957487T ATE262336T1 AT E262336 T1 ATE262336 T1 AT E262336T1 AT 98957487 T AT98957487 T AT 98957487T AT 98957487 T AT98957487 T AT 98957487T AT E262336 T1 ATE262336 T1 AT E262336T1
Authority
AT
Austria
Prior art keywords
interphenylene
trinor
methano
oxa
alpha
Prior art date
Application number
AT98957487T
Other languages
English (en)
Inventor
James W Crow
Shelmer D Blackburn Jr
Robert Roscigno
Michael Wade
Gilles Cloutier
Martine Rothblatt
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Application granted granted Critical
Publication of ATE262336T1 publication Critical patent/ATE262336T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98957487T 1997-11-14 1998-11-13 Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen ATE262336T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6604997P 1997-11-14 1997-11-14
PCT/US1998/023245 WO1999025357A1 (en) 1997-11-14 1998-11-13 USE OF 9-DEOXY-2', 9-α-METHANO-3- OXA-4,5,6- TRINOR-3, 7-(1',3'-INTERPHENYLENE) -13,14-DIHYDRO- PROSTAGLANDIN F1 TO TREAT PERIPHERAL VASCULAR DISEASE

Publications (1)

Publication Number Publication Date
ATE262336T1 true ATE262336T1 (de) 2004-04-15

Family

ID=22066941

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957487T ATE262336T1 (de) 1997-11-14 1998-11-13 Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen

Country Status (12)

Country Link
US (1) US6054486A (de)
EP (1) EP1045695B1 (de)
JP (2) JP3701870B2 (de)
KR (1) KR100638684B1 (de)
CN (1) CN1142781C (de)
AT (1) ATE262336T1 (de)
AU (1) AU1373499A (de)
CA (1) CA2312729C (de)
DE (1) DE69822665T2 (de)
ES (1) ES2214753T3 (de)
WO (1) WO1999025357A1 (de)
ZA (1) ZA9810444B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
DE60037012T2 (de) * 1999-03-18 2008-10-30 Queen Mary And Westfield College Inhibitoren der endothelin-1 synthese
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
EP1354588A1 (de) * 1999-03-18 2003-10-22 United Therapeutics Corporation et al Verfahren zur Abgabe von Benzidenprostaglandin durch Inhalation
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
CN102697790A (zh) 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
US7199157B2 (en) * 2003-12-16 2007-04-03 United Therapeutics Corporation Use of treprostinil to improve kidney functions
CN1917866B (zh) * 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
DE602005020269D1 (de) 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
CA2654492C (en) 2006-05-15 2017-06-27 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
CA2678258A1 (en) * 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
WO2009078965A1 (en) 2007-12-17 2009-06-25 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
JP6219016B2 (ja) * 2008-05-08 2017-10-25 ユナイテッド セラピューティクス コーポレーション トレプロスチニル一水和物
CN102421288B (zh) * 2009-05-07 2015-04-22 联合治疗公司 前列环素类似物的固体剂型
KR20160132501A (ko) 2010-03-15 2016-11-18 유나이티드 세러퓨틱스 코오포레이션 폐고혈압의 치료
CN103261142B (zh) 2010-06-03 2014-12-10 联合治疗公司 曲前列环素的制备
ES2581762T3 (es) 2011-03-02 2016-09-07 United Therapeutics Corporation Síntesis de producto intermedio para la producción de treprostinil
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
WO2014159050A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
EP2970081A4 (de) 2013-03-15 2016-10-12 United Therapeutics Corp Salze von treprostinil
WO2014160638A1 (en) 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
ES2908142T3 (es) 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
HU231184B1 (hu) 2014-10-08 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Treprostinil-nátrium-monohidrát és eljárás ennek előállítására
CN107108427A (zh) 2014-10-20 2017-08-29 联合治疗学有限公司 用于制备前列环素衍生物的中间体的合成
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
CA2967899C (en) 2014-12-03 2023-09-19 Steadymed Ltd Preservative-free treprostinil formulations and methods and devices for use with same
WO2018058124A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
CN119632930A (zh) 2019-04-29 2025-03-18 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
CN114616225A (zh) 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Terfostinil for use in the treatment of interstitial lung disease
AU2021289336B2 (en) 2020-06-09 2025-08-28 Mannkind Corporation Fumaryl diketopiperidine prodrugs of treprostinil
KR102849520B1 (ko) 2020-12-14 2025-08-25 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
WO2022187352A1 (en) 2021-03-03 2022-09-09 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
WO2023154705A1 (en) 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy
EP4516297A4 (de) 2022-04-29 2026-02-25 Zhaoke pharmaceutical guangzhou co ltd Treprostinil-weichnebelinhalationsmittel
CN121241041A (zh) 2023-01-19 2025-12-30 联合治疗公司 曲前列尼尔类似物及相关制备和使用方法
KR20260049630A (ko) 2023-08-08 2026-04-14 유나이티드 쎄러퓨틱스 코포레이션 경구용 삼투성 의약품 전달 시스템의 제조 방법 및 이를 사용하여 제조된 의약품 배치
CN122514512A (zh) 2023-11-09 2026-08-04 联合治疗公司 可用于生产曲前列尼尔的化合物的合成
US20260166056A1 (en) 2024-12-13 2026-06-18 United Therapeutics Corporation Treprostinil formulations and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490537A (en) * 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4306075A (en) * 1980-03-28 1981-12-15 The Upjohn Company Composition and process
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
HU190007B (en) * 1982-05-06 1986-08-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing new aromatic prostacylin analogues
SU1236380A1 (ru) * 1983-07-21 1986-06-07 Областная Клиническая Больница Г.Калинина Способ прогнозировани течени облитерирующего атеросклероза нижней конечности
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
DE4135193C1 (de) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De

Also Published As

Publication number Publication date
ZA9810444B (en) 1999-06-24
CN1285748A (zh) 2001-02-28
EP1045695A1 (de) 2000-10-25
JP2001522892A (ja) 2001-11-20
CA2312729C (en) 2006-05-23
JP3701870B2 (ja) 2005-10-05
WO1999025357A1 (en) 1999-05-27
ES2214753T3 (es) 2004-09-16
KR100638684B1 (ko) 2006-10-27
CN1142781C (zh) 2004-03-24
DE69822665D1 (de) 2004-04-29
JP2005225877A (ja) 2005-08-25
US6054486A (en) 2000-04-25
EP1045695B1 (de) 2004-03-24
DE69822665T2 (de) 2005-02-17
CA2312729A1 (en) 1999-05-27
AU1373499A (en) 1999-06-07
KR20010015807A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69024039D1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE69722681D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69534908D1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE60139466D1 (de) Behandlung von diabetes
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
BR0012921A (pt) Compostos calcilìticos
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1045695

Country of ref document: EP